Journal article icon

Journal article

Rationale, design, and organization of a randomized, controlled Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) in patients with type 2 diabetes and established cardiovascular disease.

Abstract:

Sitagliptin, an oral dipeptidyl peptidase-4 inhibitor, lowers blood glucose when administered as monotherapy or in combination with other antihyperglycemic agents. TECOS will evaluate the effects of adding sitagliptin to usual diabetes care on cardiovascular outcomes and clinical safety. TECOS is a pragmatic, academically run, multinational, randomized, double-blind, placebo-controlled, event-driven trial recruiting approximately 14,000 patients in 38 countries who have type 2 diabetes (T2DM)...

Expand abstract
Publication status:
Published

Actions


Access Document


Publisher copy:
10.1016/j.ahj.2013.09.003

Authors


Expand authors...
Journal:
American heart journal
Volume:
166
Issue:
6
Pages:
983-989.e7
Publication date:
2013-12-01
DOI:
EISSN:
1097-6744
ISSN:
0002-8703
Source identifiers:
439526

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP